Design, synthesis, and antitumor activity of novel oleanolic acid analogues targeting EGFR. 2023

Meng Yan-Qiu, and Jin-Ming Li, and Zhi-Qi Wang, and Dong-Ping Xu, and Mei-Qi Huang, and Bei-Bei Meng
Department of Pharmaceutical Engineering, Shenyang University of Chemical Technology, Shenyang 110142, China.

Based on the simulated docking of Epidermal growth factor receptor inhibitors with known active small molecule compounds, computer-aided drug design technology was used to analyze key amino acid fragments and determine the active groups binding with key sites. Then, twelve novel analogues of oleanolic acid (OA) were synthesized by introducing active groups at the C-3 and C-28 positions of OA. The structures of these novel analogues were confirmed by NMR and MS. Furthermore, the antitumor activities of these novel analogues were evaluated by MTT assay. As a result, compounds I and II showed stronger cytotoxicity on tumor cells than positive controls. In conclusion, our study synthesized twelve novel analogues of OA and determined compounds I and II had better antitumor effect, which may be potential candidate compounds for tumor therapy.

UI MeSH Term Description Entries
D009828 Oleanolic Acid A pentacyclic triterpene that occurs widely in many PLANTS as the free acid or the aglycone for many SAPONINS. It is biosynthesized from lupane. It can rearrange to the isomer, ursolic acid, or be oxidized to taraxasterol and amyrin. Oleanol,Hederins,Oleanane Triterpenes,Triterpenes, Oleanane
D004354 Drug Screening Assays, Antitumor Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals. Anticancer Drug Sensitivity Tests,Antitumor Drug Screens,Cancer Drug Tests,Drug Screening Tests, Tumor-Specific,Dye Exclusion Assays, Antitumor,Anti-Cancer Drug Screens,Antitumor Drug Screening Assays,Tumor-Specific Drug Screening Tests,Anti Cancer Drug Screens,Anti-Cancer Drug Screen,Antitumor Drug Screen,Cancer Drug Test,Drug Screen, Anti-Cancer,Drug Screen, Antitumor,Drug Screening Tests, Tumor Specific,Drug Screens, Anti-Cancer,Drug Screens, Antitumor,Drug Test, Cancer,Drug Tests, Cancer,Screen, Anti-Cancer Drug,Screen, Antitumor Drug,Screens, Anti-Cancer Drug,Screens, Antitumor Drug,Test, Cancer Drug,Tests, Cancer Drug,Tumor Specific Drug Screening Tests
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D049109 Cell Proliferation All of the processes involved in increasing CELL NUMBER including CELL DIVISION. Cell Growth in Number,Cellular Proliferation,Cell Multiplication,Cell Number Growth,Growth, Cell Number,Multiplication, Cell,Number Growth, Cell,Proliferation, Cell,Proliferation, Cellular
D066246 ErbB Receptors A family of structurally related cell-surface receptors that signal through an intrinsic PROTEIN-TYROSINE KINASE. The receptors are activated upon binding of specific ligands which include EPIDERMAL GROWTH FACTORS, and NEUREGULINS. EGF Receptor,Epidermal Growth Factor Receptor,Epidermal Growth Factor Receptor Family Protein,Epidermal Growth Factor Receptor Protein-Tyrosine Kinase,ErbB Receptor,HER Family Receptor,Receptor, EGF,Receptor, Epidermal Growth Factor,Receptor, TGF-alpha,Receptor, Transforming-Growth Factor alpha,Receptor, Urogastrone,Receptors, Epidermal Growth Factor-Urogastrone,TGF-alpha Receptor,Transforming Growth Factor alpha Receptor,Urogastrone Receptor,c-erbB-1 Protein,erbB-1 Proto-Oncogene Protein,EGF Receptors,Epidermal Growth Factor Receptor Family Proteins,Epidermal Growth Factor Receptor Kinase,HER Family Receptors,Proto-oncogene c-ErbB-1 Protein,Receptor Tyrosine-protein Kinase erbB-1,Receptor, ErbB-1,Receptors, Epidermal Growth Factor,Epidermal Growth Factor Receptor Protein Tyrosine Kinase,ErbB-1 Receptor,Family Receptor, HER,Family Receptors, HER,Proto oncogene c ErbB 1 Protein,Proto-Oncogene Protein, erbB-1,Receptor Tyrosine protein Kinase erbB 1,Receptor, ErbB,Receptor, ErbB 1,Receptor, HER Family,Receptor, TGF alpha,Receptor, Transforming Growth Factor alpha,Receptors, EGF,Receptors, Epidermal Growth Factor Urogastrone,Receptors, ErbB,Receptors, HER Family,c erbB 1 Protein,c-ErbB-1 Protein, Proto-oncogene,erbB 1 Proto Oncogene Protein

Related Publications

Meng Yan-Qiu, and Jin-Ming Li, and Zhi-Qi Wang, and Dong-Ping Xu, and Mei-Qi Huang, and Bei-Bei Meng
July 2019, Journal of Asian natural products research,
Meng Yan-Qiu, and Jin-Ming Li, and Zhi-Qi Wang, and Dong-Ping Xu, and Mei-Qi Huang, and Bei-Bei Meng
October 2017, Journal of Asian natural products research,
Meng Yan-Qiu, and Jin-Ming Li, and Zhi-Qi Wang, and Dong-Ping Xu, and Mei-Qi Huang, and Bei-Bei Meng
February 2021, Journal of Asian natural products research,
Meng Yan-Qiu, and Jin-Ming Li, and Zhi-Qi Wang, and Dong-Ping Xu, and Mei-Qi Huang, and Bei-Bei Meng
May 2013, European journal of medicinal chemistry,
Meng Yan-Qiu, and Jin-Ming Li, and Zhi-Qi Wang, and Dong-Ping Xu, and Mei-Qi Huang, and Bei-Bei Meng
November 2001, Journal of medicinal chemistry,
Meng Yan-Qiu, and Jin-Ming Li, and Zhi-Qi Wang, and Dong-Ping Xu, and Mei-Qi Huang, and Bei-Bei Meng
August 2019, MedChemComm,
Meng Yan-Qiu, and Jin-Ming Li, and Zhi-Qi Wang, and Dong-Ping Xu, and Mei-Qi Huang, and Bei-Bei Meng
July 2019, Journal of Asian natural products research,
Meng Yan-Qiu, and Jin-Ming Li, and Zhi-Qi Wang, and Dong-Ping Xu, and Mei-Qi Huang, and Bei-Bei Meng
December 2022, Journal of enzyme inhibition and medicinal chemistry,
Meng Yan-Qiu, and Jin-Ming Li, and Zhi-Qi Wang, and Dong-Ping Xu, and Mei-Qi Huang, and Bei-Bei Meng
November 2011, Medicinal chemistry (Shariqah (United Arab Emirates)),
Meng Yan-Qiu, and Jin-Ming Li, and Zhi-Qi Wang, and Dong-Ping Xu, and Mei-Qi Huang, and Bei-Bei Meng
January 2009, Bioorganic & medicinal chemistry letters,
Copied contents to your clipboard!